ARGX vs MDLN: Which Stock Is the Better Buy?
argenx SE and Medline Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARGX vs MDLN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| argenx SE (ARGX) | Medline Inc. (MDLN) | |
|---|---|---|
| Market cap | $55.7B | $64.5B |
| Revenue (latest FY) | $4.15B | $28.43B |
| Net income (latest FY) | $1.29B | $1.16B |
| Revenue growth (5y CAGR) | 116.2% | 7.0% |
| Net margin | 31.1% | 4.1% |
| Return on equity | 17.6% | 10.8% |
| P/E ratio | 39.6 | 31.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 4 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ARGX vs MDLN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARGX's full financials → Open MDLN's full financials →More comparisons
Frequently asked questions
Which is bigger, ARGX or MDLN?
Medline Inc. is larger by market capitalization — $64.5B versus $55.7B.
Which grows faster, ARGX or MDLN?
Over the last five fiscal years, argenx SE grew revenue faster — 116.2%/yr versus 7.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.